お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
991155

世界の日本脳炎ワクチン市場(2021年-2025年)

Global Japanese Encephalitis Vaccines Market 2021-2025

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.75円
世界の日本脳炎ワクチン市場(2021年-2025年)
出版日: 2021年02月23日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の日本脳炎ワクチンの市場規模は、2021年から2025年の間に5,439万米ドルの成長が見込まれており、予測期間中のCAGRは6%の見込みです。市場は、国の予防接種計画と戦略的提携によって推進されています。

当レポートでは、日本脳炎ワクチン市場を調査し、市場概要、市場の成長要因および阻害要因の分析、タイプ別・地域別の市場規模の推移と予測、ベンダー分析、市場機会など、包括的な情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模2020
  • 市場の見通し:2020年から2025年の予測

ファイブフォース分析

タイプ別の市場セグメンテーション

  • マーケット・セグメント
  • タイプ別比較
  • 不活化ワクチン-市場規模と予測(2020年~2025年)
  • 組換えワクチン-市場規模と予測(2020年~2025年)
  • 弱毒生ワクチン-市場規模と予測(2020年~2025年)
  • タイプ別の市場機会

顧客情勢

地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • アジア-市場規模と予測(2020年~2025年)
  • その他の地域-市場規模と予測(2020年~2025年)
  • 欧州-市場規模と予測(2020年~2025年)
  • 北米-市場規模と予測(2020年~2025年)
  • 主要な主要国
  • 地域の市場機会
  • 市場の推進力
  • 市場の課題
  • 市場動向

ベンダー情勢

  • 概要
  • 創造的破壊の状況

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Adimmune Corp.
  • Bharat Biotech Ltd.
  • Biological E. Ltd.
  • KM Biologics Co. Ltd.
  • Medigen Inc.
  • Panacea Biotec Ltd
  • Sanofi
  • Shandong Hengye Biotechnology Co. Ltd.
  • VA Bio+Tech Park
  • Valneva SE

付録

目次
Product Code: IRTNTR70257

Technavio has been monitoring the Japanese encephalitis vaccines market and it is poised to grow by $ 54.39 mn during 2021-2025 progressing at a CAGR of 6% during the forecast period. Our report on Japanese encephalitis vaccines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the inclusion in national immunization plan and strategic alliances. In addition, inclusion in national immunization plan is anticipated to boost the growth of the market as well.

The Japanese encephalitis vaccines market analysis includes type segment and geographical landscapes.

Technavio's Japanese encephalitis vaccines market is segmented as below:

By Type

  • Inactivated vaccines
  • Recombinant vaccines
  • Live attenuated vaccines

By Geographical Landscapes

  • Asia
  • ROW
  • Europe
  • North America

This study identifies the growing number of awareness campaigns as one of the prime reasons driving the Japanese encephalitis vaccines market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on Japanese encephalitis vaccines market covers the following areas:

  • Japanese encephalitis vaccines market sizing
  • Japanese encephalitis vaccines market forecast
  • Japanese encephalitis vaccines market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Japanese encephalitis vaccines market vendors that include Adimmune Corp., Bharat Biotech Ltd., Biological E. Ltd., KM Biologics Co. Ltd., Medigen Inc. , Panacea Biotec Ltd, Sanofi, Shandong Hengye Biotechnology Co. Ltd., VA Bio+Tech Park, and Valneva SE. Also, the Japanese encephalitis vaccines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Inactivated vaccines - Market size and forecast 2020-2025
  • Recombinant vaccines - Market size and forecast 2020-2025
  • Live attenuated vaccines - Market size and forecast 2020-2025
  • Market opportunity by Type

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • North America - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Adimmune Corp.
  • Bharat Biotech Ltd.
  • Biological E. Ltd.
  • KM Biologics Co. Ltd.
  • Medigen Inc.
  • Panacea Biotec Ltd
  • Sanofi
  • Shandong Hengye Biotechnology Co. Ltd.
  • VA Bio+Tech Park
  • Valneva SE

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Type - Market share 2020-2025 (%)
  • 22: Comparison by Type
  • 23: Inactivated vaccines - Market size and forecast 2020-2025 ($ million)
  • 24: Inactivated vaccines - Year-over-year growth 2020-2025 (%)
  • 25: Recombinant vaccines - Market size and forecast 2020-2025 ($ million)
  • 26: Recombinant vaccines - Year-over-year growth 2020-2025 (%)
  • 27: Live attenuated vaccines - Market size and forecast 2020-2025 ($ million)
  • 28: Live attenuated vaccines - Year-over-year growth 2020-2025 (%)
  • 29: Market opportunity by Type
  • 30: Customer landscape
  • 31: Market share by geography 2020-2025 (%)
  • 32: Geographic comparison
  • 33: Asia - Market size and forecast 2020-2025 ($ million)
  • 34: Asia - Year-over-year growth 2020-2025 (%)
  • 35: ROW - Market size and forecast 2020-2025 ($ million)
  • 36: ROW - Year-over-year growth 2020-2025 (%)
  • 37: Europe - Market size and forecast 2020-2025 ($ million)
  • 38: Europe - Year-over-year growth 2020-2025 (%)
  • 39: North America - Market size and forecast 2020-2025 ($ million)
  • 40: North America - Year-over-year growth 2020-2025 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: Adimmune Corp. - Overview
  • 50: Adimmune Corp. - Business segments
  • 51: Adimmune Corp. - Key offerings
  • 52: Adimmune Corp. - Key customers
  • 53: Adimmune Corp. - Segment focus
  • 54: Bharat Biotech Ltd. - Overview
  • 55: Bharat Biotech Ltd. - Product and service
  • 56: Bharat Biotech Ltd. - Key offerings
  • 57: Bharat Biotech Ltd. - Key customers
  • 58: Bharat Biotech Ltd. - Segment focus
  • 59: Biological E. Ltd. - Overview
  • 60: Biological E. Ltd. - Product and service
  • 61: Biological E. Ltd. - Key offerings
  • 62: Biological E. Ltd. - Key customers
  • 63: Biological E. Ltd. - Segment focus
  • 64: KM Biologics Co. Ltd. - Overview
  • 65: KM Biologics Co. Ltd. - Product and service
  • 66: KM Biologics Co. Ltd. - Key offerings
  • 67: KM Biologics Co. Ltd. - Key customers
  • 68: KM Biologics Co. Ltd. - Segment focus
  • 69: Medigen Inc. - Overview
  • 70: Medigen Inc. - Product and service
  • 71: Medigen Inc. - Key offerings
  • 72: Medigen Inc. - Key customers
  • 73: Medigen Inc. - Segment focus
  • 74: Panacea Biotec Ltd - Overview
  • 75: Panacea Biotec Ltd - Business segments
  • 76: Panacea Biotec Ltd - Key offerings
  • 77: Panacea Biotec Ltd - Key customers
  • 78: Panacea Biotec Ltd - Segment focus
  • 79: Sanofi - Overview
  • 80: Sanofi - Business segments
  • 81: Sanofi - Key offerings
  • 82: Sanofi - Key customers
  • 83: Sanofi - Segment focus
  • 84: Shandong Hengye Biotechnology Co. Ltd. - Overview
  • 85: Shandong Hengye Biotechnology Co. Ltd. - Product and service
  • 86: Shandong Hengye Biotechnology Co. Ltd. - Key offerings
  • 87: Shandong Hengye Biotechnology Co. Ltd. - Key customers
  • 88: Shandong Hengye Biotechnology Co. Ltd. - Segment focus
  • 89: VA Bio+Tech Park - Overview
  • 90: VA Bio+Tech Park - Product and service
  • 91: VA Bio+Tech Park - Key offerings
  • 92: VA Bio+Tech Park - Key customers
  • 93: VA Bio+Tech Park - Segment focus
  • 94: Valneva SE - Overview
  • 95: Valneva SE - Business segments
  • 96: Valneva SE - Key offerings
  • 97: Valneva SE - Key customers
  • 98: Valneva SE - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.